Oral Administration of Taurolidine Ameliorates Chronic DSS Colitis in Mice

REFERENCES

• van Montfrans C, Peppelenbosch M, te Velde A A, van Deventer S. Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. Biochem Pharmacol 2002; 64: 789–795
   PubMed Web of Science ®Google Scholar
• Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004; 20: 311–317
   PubMed Web of Science ®Google Scholar
• Allon M. Dialysis catheter-related bacteremia: Treatment and prophylaxis. Am J Kidney Dis 2004; 44: 779–791
   PubMed Web of Science ®Google Scholar
• Reith H B. [Therapy of peritonitis today. Surgical management and adjuvant therapy strategies]. Langenbecks Arch Chir 1997; 382: S14–17
   Google Scholar
• Koldehoff M, Zakrzewski J L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004; 24: 491–495
   PubMed Web of Science ®Google Scholar
• Dofferhoff A S, Esselink M T, de Vries-Hospers H G, van Zanten A, Bom V J, Weits J, Vellenga E. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 1993; 31: 373–384
   PubMed Web of Science ®Google Scholar
• Pfirrmann R W, Leslie G B. The anti-endotoxin activity of taurolin in experimental animals. J Appl Bacteriol. 1979; 46: 97–102
   PubMedGoogle Scholar
• Calabresi P, Goulette F A, Darnowski J W. Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61: 6816–6821
   PubMedGoogle Scholar
• Bedrosian I, Sofia R D, Wolff S M, Dinarello C A. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991; 3: 568–575
   PubMed Web of Science ®Google Scholar
• Sendt W, Mansouri E, Schmitt-Graeff A, Wolff-Vorbeck G, Schoffel U. Influence of antiseptic agents on interleukin-8 release and transmigration of polymorphonuclear neutrophils in a human in vitro model of peritonitis. Surg Infect (Larchmt) 2002; 3: 235–244
   PubMedGoogle Scholar
• Rosman C, Westerveld G J, van Oeveren W, Kooi K, Bleichrodt R P. Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. Eur Surg Res 1996; 28: 351–360
   PubMed Web of Science ®Google Scholar
• Rosman C, Westerveld G J, Kooi K, Bleichrodt R P. Local treatment of generalised peritonitis in rats; Effects on bacteria, endotoxin and mortality. Eur J Surg 1999; 165: 1072–1079
   PubMedGoogle Scholar
• Watson R W, Redmond H P, Mc Carthy J, Bouchier-Hayes D. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. J Leukocyte Biol 1995; 58: 299–306
   PubMed Web of Science ®Google Scholar
• Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694–702
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss I J, Blumberg R S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495–549
   PubMed Web of Science ®Google Scholar
• Cooper H S, Murthy S N, Shah R S, Sedergran D J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238–249
   PubMed Web of Science ®Google Scholar
• Murthy S N, Cooper H S, Shim H, Shah R S, Ibrahim S A, Sedergran D J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993; 38: 1722–1734
   PubMed Web of Science ®Google Scholar
• Gardiner K R, Anderson N H, McCaigue M D, Erwin P J, Halliday M I, Rowlands B J. Enteral and parenteral anti-endotoxin treatment in experimental colitis. Hepatogastroenterology 1994; 41: 554–558
   PubMedGoogle Scholar
• Steinbach-Lebbin C, Ganz A J, Chang A, Waser P G. [Pharmacokinetics of taurolin]. Arzneim Forschung 1982; 32: 1542–1546
   PubMedGoogle Scholar
• Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: G417–421
   Web of Science ®Google Scholar
• Sartor R B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620–1633
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253–2286
   PubMed Web of Science ®Google Scholar
• Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288: G1328–1338
   PubMed Web of Science ®Google Scholar
• Chromik A M, Muller A M, Korner J, Belyaev O, Holland-Letz T, Schmitz F, Herdegen T, Uhl W, Mittelkotter U. Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice. J Invest Surg 2007; 20: 23–33
   PubMed Web of Science ®Google Scholar
• Egger B, Procaccino F, Lakshmanan J, Reinshagen M, Hoffmann P, Patel A, Reuben W, Gnanakkan S, Liu L, Barajas L, Eysselein V E. Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 1997; 113: 825–832
   PubMed Web of Science ®Google Scholar
• Schultz M, Strauch U G, Linde H J, Watzl S, Obermeier F, Gottl C, Dunger N, Grunwald N, Scholmerich J, Rath H C. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11: 372–378
   PubMedGoogle Scholar
• Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci. 2004; 49: 320–327
   PubMed Web of Science ®Google Scholar
• Osman N, Adawi D, Molin G, Ahrne S, Berggren A, Jeppsson B. Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. BMC Gastroenterol 2006; 6: 31
   PubMed Web of Science ®Google Scholar
• Sakuraba H, Ishiguro Y, Yamagata K, Tagawa Y, Iwakura Y, Sekikawa K, Munakata A, Nakane A. Transforming growth factor-beta regulates susceptibility of epithelial apoptosis in murine model of colitis. Ann NY Acad Sci 2004; 1029: 382–384
   PubMed Web of Science ®Google Scholar
• Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 2007
   PubMedGoogle Scholar
• Tsubouchi R, Hayashi S, Aoi Y, Nishio H, Terashima S, Kato S, Takeuchi K. Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. Digestion 2006; 74: 91–100
   PubMed Web of Science ®Google Scholar
• Martin A R, Villegas I, Alarcon de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 2005; 54: 145–151
   PubMed Web of Science ®Google Scholar
• Jacobi C A, Menenakos C, Braumann C. Taurolidine—A new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 917–921
   PubMedGoogle Scholar
• Mudter J, Neurath M F. Mucosal T cells: Mediators or guardians of inflammatory bowel disease?. Curr Opin Gastroenterol 2003; 19: 343–349
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak J F, Lehr H A, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle P R, Rose-John S, Neurath M F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583–588
   PubMed Web of Science ®Google Scholar
• Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, Chinen H, Hong K S, Yamada T, Suzuki Y, Suzuki T, Watanabe N, Tsuchimoto K, Hibi T. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis. 2005; 11: 455–463
   PubMed Web of Science ®Google Scholar
• Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods 2001; 25: 386–401
   PubMed Web of Science ®Google Scholar
• Arita M, Yoshida M, Hong S, Tjonahen E, Glickman J N, Petasis N A, Blumberg R S, Serhan C N. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005; 102: 7671–7676
   PubMed Web of Science ®Google Scholar
• Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 2003; 14: 33–43
   PubMedGoogle Scholar
• Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002; 32: 2084–2092
   PubMed Web of Science ®Google Scholar